Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (DE:4TZ)
FRANKFURT:4TZ
RESEARCH TOOLSreports
Oric Pharmaceuticals (4TZ) Stock Price & Analysis
0 Followers
4TZ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.44 - €14.80
Previous Close€8.25
Volume0.00
Average Volume (3M)886.00
Market Cap
€551.39M
Enterprise Value€356.21M
Total Cash (Recent Filing)$208.19M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.91
Next Earnings
May 06, 2024EPS Estimate
-€0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding67,375,847
10 Day Avg. Volume0
30 Day Avg. Volume886
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.36
Forecast
1Y Price Target
€18.93Price Target Upside129.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Oric Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe monotherapy data showed low variability between patients, and no signs of CYP autoinduction.
Drug Development ProgressInitial Phase 1b PK/PD data for ORIC-944 showed favorable drug properties.
Financial HealthORIC ended the quarter with substantial cash reserves, supporting its operations and development programs well into the future.
Bears Say
Clinical Development RisksRisks include, but are not limited to: inability to advance ORIC-533, ORIC-114 and ORIC-944 in clinical development; negative clinical data with these pipeline candidates; delays in moving into pivotal clinical trials.
Clinical Trialsour doc doesn't like to stack enza directly following abiraterone, based on poorer PFS data than following with chemo
Study Design Concernsnot totally confident whether the study will be powered for statistical significance (each arm is ≤40 patients)
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.30% Other Institutional Investors
98.70% Public Companies and
Individual Investors
4TZ FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was €4.44 and its highest was €14.80 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Currently, no data Available
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is in 11 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Mar 11, 2024. The company reported -€0.459 earnings per share for the quarter, missing the consensus estimate of -€0.448 by -€0.011.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -€0.4.
How many shares outstanding does Oric Pharmaceuticals have?
Currently, no data Available
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -€0.459 in its last earnings report, missing expectations of -€0.448. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Among the largest hedge funds holding Oric Pharmaceuticals’s share is Invus Financial Advisors, LLC. It holds Oric Pharmaceuticals’s shares valued at 9M.
---
Oric Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.93 (129.50% Upside)
€18.93 (129.50% Upside)
Blogger Sentiment
Bullish
DE:4TZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.48%
12-Months-Change
Fundamentals
Return on Equity
-45.11%
Trailing 12-Months
Asset Growth
1.73%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
---
4TZ Stock 12 Months Forecast
Average Price Target
€18.93
▲(129.50% Upside)
Technical Analysis
Oric Pharmaceuticals
―
Oramed Pharm
―
BioCryst
―
Avadel Pharmaceuticals
―
Summit Therapeutics
―
Best Analysts Covering 4TZ
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+19.74%
reiterated a buy rating last month
Copying Anupam Rama's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +19.74% per trade.
---